NEW YORK (GenomeWeb News) – DiaTech Oncology has struck a license agreement with Vanderbilt University for a microkinetic assay that can be used to determine a patient's chemotherapy treatment and dosing needs, the university said today.
The Brentwood, Tenn.-based company has licensed the MiCK test, which was developed at the Vanderbilt University School of Medicine, which will be used in a service that measures the response through apoptosis of patients' cancer cells to a number of different chemotherapeutic drugs.
A lab analysis of the cancer cells is conducted in order to monitor and then compute the amounts of apoptosis caused by each of the drugs. DiaTech plans to provide oncologists with a drug-sensitivity profile for the patient within 24 to 48 hours.
Financial terms of the agreement were not released.